Tag: whole-genome testing
-
MyOme Unveils Polygenic Risk Score for Prostate Cancer
Introduction: A New Era in Prostate Cancer Risk Assessment MyOme, a leader in clinical whole-genome testing, has announced the launch of the first integrated polygenic risk score (PRS) for prostate cancer. This groundbreaking test goes beyond traditional screening by examining a broad array of genetic variants across the genome to identify hidden risk factors. The…
-
MyOme Unveils Integrated Polygenic Risk Score for Prostate Cancer to Advance Early Detection
Overview: A New Era in Prostate Cancer Risk Assessment MyOme, a leading name in clinical whole-genome testing, has announced the launch of the first integrated polygenic risk score (PRS) for prostate cancer. This innovative approach combines a patient’s entire genome with sophisticated algorithms to estimate lifetime risk more precisely than traditional screening methods alone. The…
-
MyOme Unveils First Integrated Polygenic Risk Score for Prostate Cancer to Drive Early Detection and Personalized Prevention
Introduction: A New Era in Prostate Cancer Risk Assessment MyOme has introduced the first integrated polygenic risk score (PRS) for prostate cancer, packaged within its comprehensive whole-genome testing platform. This breakthrough combines multiple genetic signals across the genome to deliver a nuanced risk profile, going beyond traditional screening methods. The goal is to identify men…